This page shows the latest Remestemcel-L news and features for those working in and with pharma, biotech and healthcare.
Shares in Mesoblast dropped sharply after Novartis pulled out of a deal announced earlier this year to collaborate on COVID-19 medicine remestemcel-L, citing poor trial data. ... When it announced a deal with Australian inflammatory disease specialist
Remestemcel-L was being studied in patients with COVID-19-related acute respiratory distress. ... Remestemcel-L was being studied in ventilator-dependent COVID-19 patients with moderate-to-severe acute respiratory distress (ARDS).
The drug, an allogeneic mesenchymal stem cell (MSC) product candidate dubbed remestemcel-L, will now be available for children between the ages of two months and 15 years old infected with ... Remestemcel-L is comprised of culture-expanded mesenchymal
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...